Winter 2024 (Volume 34, Number 4)

Arthritis Society Canada and Creative Destruction Lab Announce Four Innovators Poised to Advance Arthritis Innovations

Download PDF

Ahead of World Arthritis Day on October 12th, Arthritis Society Canada, in partnership with Creative Destruction Lab (CDL), announced four arthritis-focused companies selected to join CDL’s world-class program for massively scalable, seed-stage, science- and technology-based companies. They will spend the next nine months developing and bringing their innovations to market to improve the quality of life of people living with arthritis.

The selected innovators are:

1. Canurta Therapeutics – a biotechnology company addressing unmet needs in neurodegenerative diseases, including ALS, dementia, rheumatoid and juvenile arthritis, by developing rare botanical drugs.
2. Interface Biosciences – using a novel discovery platform that integrates artificial intelligence to develop therapies for autoimmune diseases, including rheumatoid arthritis and cancer.
3. SereNeuro Therapeutics – spearheading non-opioid pain therapies for long-term pain relief, using advanced cell and gene therapy for chronic pain, including applications for juvenile arthritis and other types of arthritis.
4. A new company (yet to be public) – advancing precision therapeutics targeting the root causes of inflammation in antibody-mediated diseases like rheumatoid and psoriatic arthritis.

These companies, along with 15 other seed-stage ventures, will gain mentorship and resources to launch their innovations. In Spring 2025, Arthritis Society Canada and CDL will celebrate their contributions to the future of arthritis care at an inaugural showcase event.

Learn more about Arthritis Society Canada’s leadership in driving innovative solutions at arthritis.ca.